Boston Scientific (BSX) Common Equity (2009 - 2026)

Boston Scientific has disclosed Common Equity across 18 years of filings, most recently posting $25.2 billion for Q2 2026.

• In Q2 2026, Common Equity rose 11.12% year-over-year to $25.2 billion; the TTM figure through Jun 2026 stood at $25.2 billion (up 11.12% YoY), while the FY2025 annual figure was $24.5 billion, up 11.22% from the prior year.
• Common Equity came in at $25.2 billion for Q2 2026 at Boston Scientific, down from $26.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $26.1 billion in Q1 2026 to a low of $16.7 billion in Q1 2022.
• Average Common Equity over 5 years is $20.7 billion, with a median of $20.4 billion recorded in 2024.
• Year-over-year, Common Equity advanced 5.72% in 2022 and grew 16.3% in 2026.
• Over 5 years, Common Equity stood at $17.6 billion in 2022, then climbed by 11.14% to $19.5 billion in 2023, then climbed by 12.66% to $22.0 billion in 2024, then climbed by 11.22% to $24.5 billion in 2025, then advanced by 2.86% to $25.2 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $25.2 billion in Q2 2026, $26.1 billion in Q1 2026, and $24.5 billion in Q4 2025.